{
    "organizations": [],
    "uuid": "fbcaa2e5423792ff9785e73fac92bf803f0939c7",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novo-nordisk-says-diabetes-drug-oz/brief-novo-nordisk-says-diabetes-drug-ozempic-has-been-approved-in-the-eu-idUSFWN1PZ0XQ",
    "ord_in_thread": 0,
    "title": "BRIEF-Novo Nordisk Says Diabetes Drug Ozempic Has Been Approved In The EU",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 9 (Reuters) - NOVO NORDISK:\n* OZEMPIC (SEMAGLUTIDE) APPROVED IN EU FOR TREATMENT OF TYPE 2 DIABETES​\n* SAYS ‍OZEMPIC HAS BEEN APPROVED IN EU FOR USE IN A MULTI-DOSE PEN, HOWEVER, NOVO INTENDS TO SUBMIT A VARIATION APPLICATION TO EUROPEAN MEDICINES AGENCY (EMA) SEEKING APPROVAL OF AN UPDATED OZEMPIC PEN OFFERING\n* OZEMPIC WAS APPROVED BY THE U.S. FDA ON 5 DECEMBER 2017 SOURCE TEXT FOR EIKON: FURTHER COMPANY COVERAGE: (Reporting by Stine Jacobsen)\n ",
    "published": "2018-02-09T19:42:00.000+02:00",
    "crawled": "2018-02-10T14:15:24.010+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "novo",
        "nordisk",
        "ozempic",
        "semaglutide",
        "approved",
        "eu",
        "treatment",
        "type",
        "say",
        "approved",
        "eu",
        "use",
        "pen",
        "however",
        "novo",
        "intends",
        "submit",
        "variation",
        "application",
        "european",
        "medicine",
        "agency",
        "ema",
        "seeking",
        "approval",
        "updated",
        "ozempic",
        "pen",
        "offering",
        "ozempic",
        "approved",
        "fda",
        "december",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "reporting",
        "stine",
        "jacobsen"
    ]
}